10-Q: Charlotte's Web Q3 2026: Revenue Declines Amidst Regulatory Headwinds

Charlotte's Web Holdings reported a significant revenue decrease in Q3 2026, alongside an increased net loss, as the company navigates evolving hemp regulations and strategic shifts.

Summary

• Charlotte's Web Holdings reported a net loss of $3.46 million for the third quarter of 2026, compared to a net loss of $5.82 million in the same period of 2025.
• Total revenue for Q3 2026 was $9.39 million, an 18.3% decrease from $11.50 million in Q3 2025.
• The company experienced a 14.1% decrease in total revenue for the first nine months of 2026, reaching $31.41 million compared to $36.57 million in the prior year period.
• Gross margin improved to 46.9% in Q3 2026 from 38.9% in Q3 2025, driven by product mix, insourcing savings, and reduced discounts.
• Selling, general, and administrative expenses decreased by 16.8% in Q3 2026 due to lower debt amortization costs and reduced media spending.
• The company completed a significant transaction with BAT on May 28, 2026, converting a convertible debenture and receiving an additional equity investment, which eliminated debt and provided new capital.
• Regulatory changes, particularly in California and upcoming federal restrictions on THC/CBD limits, are impacting product sales and require potential reformulation.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, increased net losses, and ongoing regulatory uncertainties impacting the hemp industry.

Positives

• Gross margin improved to 46.9% in Q3 2026 from 38.9% in Q3 2025, attributed to better product and channel mix, operational efficiencies from insourcing, and reduced promotional discounts.
• Selling, general, and administrative expenses decreased by 16.8% in Q3 2026, primarily due to reduced debt amortization costs following the debt conversion and lower investment in paid media.
• The company successfully converted its significant convertible debenture with BAT and secured an additional $10 million in equity, strengthening its balance sheet and eliminating debt.
• The company is actively diversifying its product portfolio beyond CBD to include functional mushrooms, minor cannabinoids, and hemp-derived THC products.
• The company's investment in DeFloria, a collaboration for developing AJA001 for ASD symptoms, has progressed to Phase 2 clinical trials.

Negatives

• Total revenue for Q3 2026 decreased by 18.3% to $9.39 million compared to $11.50 million in Q3 2025.
• Revenue for the first nine months of 2026 decreased by 14.1% to $31.41 million compared to $36.57 million in the same period of 2025.
• Net loss for Q3 2026 was $3.46 million, an increase from $5.82 million in Q3 2025, indicating a worsening loss on a per-share basis.
• The company incurred a $4.2 million loss from the extinguishment of debt related to the conversion of the convertible debenture.
• An inventory provision of $1.365 million was recorded in Q3 2026, impacting cost of goods sold, related to the annihilation of aged and obsolete inventory.
• The company faces significant uncertainty and potential negative impacts from upcoming federal restrictions on THC/CBD limits, which could render some of its full-spectrum products non-compliant with the definition of hemp.

Risks

• Upcoming federal restrictions scheduled to become effective December 11, 2026, may cause certain full-spectrum products to no longer meet the federal definition of hemp, potentially impacting sales.
• The company is evaluating potential product reformulations and other actions to mitigate the impact of new federal regulations, with uncertain outcomes.
• Evolving state regulations, such as those in California, have impacted and may continue to impact product sales and require adjustments to product formulations and packaging.
• The company's ability to fund operations long-term depends on future operating performance, revenue growth, expense management, and external factors like economic conditions and regulatory changes.
• The company's investment in DeFloria is subject to estimation uncertainty due to the use of Level 3 fair value inputs and an Option Pricing Model.
• The company's financial results are subject to the fair value fluctuations of financial instruments, including its investment in DeFloria and debt derivatives.

Future Outlook

The company expects continued cost containment in SG&A expenses for the remainder of 2026. Management believes existing cash and cash equivalents will fund operations and planned capital expenditures for the next 12 months. Longer-term funding depends on operating performance, revenue growth, expense management, and external factors. The company may pursue additional capital through borrowings or equity/debt issuances.

Management Comments

• Management believes that the Company's existing cash and cash equivalents, and short-term investments will provide sufficient liquidity to fund operations and planned capital expenditures for the next 12 months.
• The Company expects a continued cost containment strategy in overall selling, general, and administrative expenses in the remainder of 2026 as a result of several actions taken over the prior two years.

Industry Context

StockSavvy.ai notes that Charlotte's Web is operating in a dynamic and evolving hemp and CBD market. The recent federal legislative changes regarding THC/CBD limits and ongoing state-level regulatory shifts present significant challenges and opportunities for product development and market access. The company's strategic pivot towards diversification into functional mushrooms, minor cannabinoids, and THC products reflects a broader industry trend to expand beyond traditional CBD offerings.

Comparison to Industry Standards

• The company's gross margin of 46.9% for Q3 2026 shows improvement over the prior year's 38.9%, indicating better pricing power or cost control relative to its own historical performance.
• The decline in revenue (-18.3% YoY for Q3) suggests a challenging market environment for CBD products, potentially impacting competitors as well, though specific competitor data is not provided in this filing.
• The company's focus on R&D and clinical trials for hemp-derived compounds, such as AJA001 for ASD symptoms, aligns with a growing trend in the industry towards scientifically validated therapeutic applications.
• The company's strategic diversification into functional mushrooms and minor cannabinoids mirrors efforts by other wellness companies to capture broader market segments and reduce reliance on a single product category.

Legal Proceedings

• Management believes that as of September 30, 2026, there is no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company's financial position, results of operations or cash flows.
• The Company is not a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business.

Related Party Transactions

• The company has an accounts receivable balance due from DeFloria of $1,764,000 as of September 30, 2026.
• The company entered into an amended and restated convertible promissory note with DeFloria with an aggregate principal amount of $1,583,000 as of August 14, 2026.
• The company entered into a consulting agreement with Jared Stanley, former executive and board member, for a bi-weekly fee of $6,000.
• The company has a supply agreement with DeFloria, charging at cost of goods sold level for raw materials.
• The company has a master services agreement with DeFloria for provision of certain services.

Stakeholder Impact

• Shareholders may be impacted by the declining revenue and increased net loss, potentially affecting share price.
• Employees may be impacted by cost-cutting measures and workforce adjustments mentioned in the SG&A expense reduction.
• Suppliers may be impacted by the company's decision to reduce lower-margin retail distribution.
• Creditors are not directly impacted by immediate concerns, as the company has secured additional equity and eliminated convertible debt.

Next Steps

• The company is evaluating potential product reformulations and other actions to mitigate the impact of upcoming federal restrictions on THC/CBD limits.
• The company is preparing for potential participation in the Center for Medicare and Medicaid Innovation (CMMI) pilot program in 2027.
• The company continues to assess the business and financial impacts of new state regulations and steps to address new product formulation and labeling requirements.
• The company is engaging with policymakers and industry organizations regarding potential regulatory approaches to hemp-derived products.

Key Dates

Recommendation

While the company has improved gross margins and managed SG&A expenses, the significant decline in revenue and increasing net losses are concerning. The ongoing regulatory uncertainty, particularly regarding federal THC/CBD limits, poses a substantial risk. The conversion of debt and new equity injection provide some financial stability, but the path to profitability remains unclear. Therefore, a 'hold' recommendation is appropriate pending clearer regulatory outcomes and a demonstrated return to revenue growth.

Keywords

CBD, Hemp Extract, Wellness Products, Functional Mushrooms, Minor Cannabinoids, THC, Regulatory Compliance, Financial Statements